Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICC APL STUDY 02
2024-518669-83-00Phase 2Authorised
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and tretinoin in Acute promyelocytic leukaemia (APL), sponsored by Italian Association of Pediatric Hematology and Oncology. Primary endpoint: Event-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
arsenic trioxidetretinoin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on 2024-518669-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518669-83-00.